EMVision completes pilot line, receives $1.25 million grant payment

Brain imaging company EMVision Medical Devices has completed its pilot commercial line and received a third and final milestone-related payment, worth $1.25 million, under the federal Modern Manufacturing Initiative.

EMVision is developing bedside and portable machines for detecting stroke, with the former (known as emu) currently in clinical trials.

In a statement to the ASX on Monday, EMVision said the newly-completed pilot line for the first-generation product at Macquarie Park “has the initial capacity to build, test and release approximately one emu brain scanner per week”.

The company was awarded a $5 million grant under the Modern Manufacturing Initiative’s Manufacturing Translation Stream in October 2022. This came with a $2 million initial grant payment, and another $1.75 million payment in June last year.

EMVision was spun out of University of Queensland in 2017 to commercialise techniques using low-power microwaves to rapidly map brain tissue. 

The company’s devices are designed to detect if a stroke has occurred within minutes so treatment can be more rapidly decided on versus established methods.

Further reading

EMVision receives $1.75 million grant milestone payment

Government grants EMVision funding for brain scanner

EMVision moves to new trial phase of stroke detector

Medtech innovator explains the rush to save brains